Category Archives: Drug Discovery

Predicting ADME Properties with Machine Learning: 82% of the Performance From Two Descriptors

A Nature survey of ~1500 scientists reported that more than 70% had failed to reproduce another scientist’s experiments, and 50% had failed to replicate their own (Baker, 2016). This study wasn’t specific to machine learning, but the crisis has its own flavour in computational drug discovery.

One aspect of this is that available datasets have known quality issues, and results built on them can be fragile. MoleculeNet and the Therapeutic Data Commons (TDC) opened drug discovery to a wider ML community, but they’re no longer sufficient for driving further advances (Wognum et al., 2024).

Amongst a number of issues, 71% of molecules in one MoleculeNet dataset (BACE) contained at least one undefined stereocenter (a point where the same atoms can sit in two different 3D arrangements), making it unclear what chemical entity is actually being modelled (Li et al., 2026).

The stakes are high. In 2017, a research group found their cancer-target inhibitor inactive from one vendor and highly active from another. Eventually they traced this to vendors selling different mixtures of the compound’s two 3D forms where only one was active on the target and mechanism they were investigating (Baker, 2017).

Most approved pharmaceuticals are relatively small chemical molecules, typically weighing under 900 g/mol, with most of the rest being biologics. Whilst in Oxford on the UNIQ+ summer internship programme, I focused on ADME, an aspect of early stage drug discovery, where assays are measured in vitro as a stand-in to predict how a compound will behave in vivo (in the human body) before clinical trials. Absorption (does it enter the body), Distribution (where does it go), Metabolism (how quickly it’s transformed) and Excretion (how quickly it’s eliminated) are processes critical to whether a candidate succeeds. 

Continue reading →

Beyond the Vaccine: AI’s Expanding Role in LNP mediated Drug Delivery

Lipid nanoparticles (LNPs) have evolved from a specialised drug-delivery technology into a cornerstone of modern medicine. Their success became evident during the COVID-19 pandemic, enabling the delivery of the mRNA used in the Pfizer-BioNTech and Moderna vaccines. However, their applications extend far beyond vaccination, as LNPs can also deliver siRNA, plasmid DNA and gene-editing machinery, creating opportunities to treat genetic diseases, cancer and many other conditions.

Yet a fundamental challenge remains: how do we design an LNP that delivers the right payload, to the right cells, in the right place?

Continue reading →

A Golden Age of Nanomedicine

As someone who spent their entire academic career, from B.Sc. to M.Sc. to Ph.D., within a Kavli Institute for Nanoscience Discovery (first in Delft and now in Oxford), I’ve had the privilege of seeing firsthand just how beautifully intricate the nanoscale world can be. Now, as my research focuses on lipid nanoparticles for genetic therapeutics and vaccines, I would like to use this platform to advocate for what I believe is one of the most transformative frontiers in modern medicine: the rational design of nanomaterials for therapeutic delivery.

Continue reading →

A first for PROTACs

Last week marked a major milestone in small-molecule drug discovery with the first FDA approval of a proteolysis targeting chimera (PROTAC). After a modest but successful phase 3 clinical trial demonstrated a 2.9 month improvement in median progression free survival1 for a type of advanced breast cancer1, the FDA has approved Veppanu (vepdegestrant), co-developed by Arvinas and Pfizer, as the first PROTAC protein degrader therapy2. So what is a PROTAC?

Continue reading →

SigmaDock: untwisting molecular docking with fragment-based SE(3) diffusion

Alvaro Prat, Leo Zhang, Charlotte Deane, Yee Whye Teh, & Garrett M. Morris
International Conference On Learning Representations (ICLR 2026)

Molecular docking sits at the heart of structure-based drug discovery. If we can reliably predict how a small molecule binds in a protein pocket, we can prioritize compounds faster, reason about interactions more clearly, and build better pipelines for hit discovery and lead optimization. But in practice, docking is still a difficult problem: classical methods are often robust but imperfect, while recent deep learning approaches have sometimes looked promising on headline metrics without consistently producing chemically plausible poses.

SigmaDock was built to address exactly that gap. Instead of treating docking as a problem of directly diffusing on torsion angles or unconstrained atomic coordinates, SigmaDock represents ligands as collections of rigid fragments and learns how to reassemble them inside the binding pocket using diffusion on SE(3)\text{SE}(3). In plain English: rather than trying to “wiggle” every flexible degree of freedom in a tangled way, SigmaDock breaks the ligand into chemically meaningful rigid pieces and learns where those pieces should go, and how they should reorient, to recover a valid bound pose.

Figure 1: Illustration of SigmaDock using PDB 1V4S and ligand MRK. We create an initial conformation of a query ligand where we define our mm rigid body fragments (colour coded). The corresponding forward diffusion process operates in SE(3)m\text{SE}(3)^m via independent roto-translations.
Continue reading →

Design your very own drug: An introduction to structure-based small molecule drug design

Are you curious about how scientists design small molecules to treat disease using computational tools, but the words RDKit, docking, and QED mean nothing to you? Look no further than these tutorials for learning the fundamentals of computational small molecule drug design through interactive tutorials that introduce the key tools, concepts, and workflows. From generating compounds to evaluating their drug-likeness and binding potential, by the end you’ll be ready to explore how computational methods can result in the discovery of your very own (virtual) drug candidates to cure Zika!

Find the materials here: https://github.com/oxpig/dtc-struc-bio-smolecules/tree/main.

Continue reading →

Nanobodies® galore in Utrecht

At the end of September, I had the opportunity to present at the 4th Single-Domain Antibody (sdAb/VHH) Conference hosted in the city of Utrecht. The sdAb conference is a biennial event, and was held for the first time in Bonn (2019), then in Brussels (2021) and Paris (2023), before coming to the Netherlands this year.

This was the first time I’d attended a VHH-focused conference, and I was taken aback at just how large the community is; the Jaarbeurs ‘Supernova’ event hall was completely sold out, with over 400 researchers in attendance (pictures below courtesy of the organisers). The buzz reflects the ever growing interest in sdAbs as tools to discover new fundamental biology, vectors for diagnosing disease, and as prophylactic or curative therapeutics. Most every disease indication was represented at the conference, from anticancer and antiviral sdAbs to antivenom sdAbs (both for use in lateral flow tests to diagnose the snake that bit you, and as quick ‘epipen’-like therapeutics accessible even in the most remote parts of the world).

Continue reading →

Reflections on GRC CADD 2025: A Week of Insight, Innovation, and Baseball

Henry

Back in July, some very lucky OPIGlets ventured across the pond to discover life in Southern Maine (and Boston!). For someone visiting Boston for the first time, no trip would be complete without a Red Sox game—a thoroughly enjoyable highlight (see Figure 1). While we were there, we also went to Gordon Research Conference (GRC) on Computer Aided Drug Design (CADD).

A flock of OPIGlets taking in the Fenway Park experience at a Red Sox game.
Continue reading →

How reliable are affinity datasets in practice?

The Data Bottleneck in AI-Powered Drug Discovery

The pharmaceutical industry is undergoing a profound transformation, driven by the promise of Artificial Intelligence (AI) and Machine Learning (ML). These technologies offer the potential to escape the industry’s persistent challenges of high costs, protracted development timelines, and staggering failure rates. From accelerating the identification of novel biological targets to optimizing the properties of lead compounds, AI is poised to enhance the precision and efficiency of drug discovery at nearly every stage

Yet, this revolutionary potential is constrained by a fundamental dependency. The power of modern AI, particularly the deep learning (DL) models that excel at complex pattern recognition, is directly proportional to the volume, diversity, and quality of the data they are trained on. This creates a critical bottleneck: the high-quality experimental data required to train these models—specifically, the protein-ligand binding affinity values that quantify the strength of an interaction—are notoriously scarce, expensive to generate, and often of inconsistent quality or locked within proprietary databases.

Continue reading →

Can AI help us design better viruses?

Viruses are the most abundant biological entity on the planet. They infect virtually every kind of life form including (sort of) other viruses. Viruses are intensely efficient – some viruses contain as few as 4 genes. Their strategy is typically simple: infect a cell, use its machinery to produce more viruses, and spread to other cells.

Pathogenic human viruses are terrible, but there are many other viruses which are useful for humans. For instance, many modern vaccines use viral vectors to produce antigens of other pathogenic entities. There is also growing interest in using viruses to fight off bacterial infections.

Continue reading →